This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $405,230 in funding to Rafias LLC to advance NR4A1 as a novel target for treating cocaine use disorder. The objectives are to: (1) Identify lead NR4A1-activating compounds through synthesis and screening of Cytosporone B derivatives, and (2) Characterize the lead compound(s) using binding assays, synthetic feasibility, and pharmacokinetics. This...
This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), provides $234,000.00 to Oregon Health & Science University (OHSU) to investigate the mechanisms underlying the incubation of cocaine craving. The key objectives are to use translating ribosome affinity purification followed by RNA sequencing (TRAP-seq) to identify mRNAs that are actively translated in the nucleus accumbens of rats during re-exposure...
The National Institute on Drug Abuse (NIDA), an agency within the U.S. Department of Health and Human Services, awarded a $1,447,919 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Pennsylvania State University to conduct research on cocaine addiction and the "need-state hypothesis." The key objectives are to: Test whether treatment with a GLP-1 receptor agonist can block the aversive behavioral and physiological responses to a cocaine-predictive cue...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under CFDA Program 93.279 "Drug Use and Addiction Research Programs," provides $711,875 to the University of Massachusetts Medical School (UMass Medical) to explore the role of the neuropeptide nociceptin in suppressing cocaine reward. The 2-year project from June 2024 to May 2026 will leverage cutting-edge viral and genetic tools to characterize nociceptin signaling in the nucleus accumbens and its...
The $858,600 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to identify and validate G protein-coupled receptors (GPCRs) expressed by somatostatin-expressing inhibitory neurons in the prefrontal cortex as potential targets for developing novel treatments for opioid use disorder (OUD). The research aims to take an unbiased transcriptomics approach to identify GPCR transcripts in these...
This $419,876 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a preclinical trial to investigate the use of NPS receptor-targeted molecules to mitigate opioid addiction. The research aims to determine if these molecules can reduce oxycodone self-administration and decrease the motivation to obtain oxycodone in animal models. The project is being conducted by The Research Foundation for the State...
This $319,547 project grant awarded on September 15, 2023 by the National Institute on Drug Abuse (NIDA) under the Drug Abuse and Addiction Research Programs (CFDA 93.279) supports Afasci, Inc.'s research and development of a novel treatment for cocaine use disorder (CUD). The project will investigate the effects of Afasci's investigational new drug AFA-281, which inhibits both the T-type Cav3 ion channels and soluble epoxide hydrolase, on reducing cocaine-seeking behavior and hyperlocomotion in...
This $1,749,120 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research focused on understanding the underlying neurobiology and behavioral mechanisms driving the incubation of craving for the opioid oxycodone. The research team at Oregon Health & Science University will use an animal model to investigate how specific neural pathways and synaptic plasticity changes in the nucleus...
This Cooperative Agreement awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $11,872,077 in funding to Sparian Biosciences Inc. (doing business as Palion Therapeutics) for the development of SBS-226, a novel chemical entity targeting the mu-opioid receptor (MOR) and delta-opioid receptor (DOR) for the treatment of opioid use disorder (OUD). The project involves comprehensive IND-enabling development and a Phase 1...
This $13,718,085 Cooperative Agreement, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the clinical development of PF614-MPAR, an opioid analgesic with built-in abuse-deterrent and overdose protection features. The key product being developed is PF614-MPAR, a combination product comprising the TAAP-oxycodone prodrug PF614 and the trypsin inhibitor nafamostat. This novel formulation is designed to provide pain...